Beam Therapeutics is trading 4.1% up now at $26.98 after the company provided a positive financial outlook and clinical milestones that outweighed second-quarter earnings misses.
- Management extended the company’s cash runway guidance into mid-2029, providing significant long-term financial stability.
- Investor sentiment was bolstered by progress in the pivotal BEAM-302 trial, overshadowing a reported net loss and thin collaboration revenue.
- The updated guidance and clinical roadmap have reassured markets despite the company missing both revenue and EPS estimates for the quarter.